Schedule 13G ownership disclosure
Apellis Pharmaceuticals Inc
Common Stock, $0.0001 par value per share · CUSIP: 03753U106
Event date: 2025-05-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deep Track Capital, LP
Shares: 7,000,000.00 · Class: 5.57%
- Deep Track Biotechnology Master Fund, Ltd.
Shares: 7,000,000.00 · Class: 5.57%
- David Kroin
Shares: 7,000,000.00 · Class: 5.57%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001172661-25-002414
- Form type
- SCHEDULE 13G
- Filer
- Apellis Pharmaceuticals, Inc.
- CIK
- CIK 1492422
- Filed
- May 16, 2025
- Reporting period
- May 09, 2025
- Description
- Schedule 13G beneficial ownership